clinical trial · NCT07851220
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Glomerulonephritis, MembranousInebilizumabTacrolimus
brief summary
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
started
Oct 1, 2026
primary completion
Sep 27, 2031
completion
Sep 26, 2033
last updated
Oct 1, 2026
official title
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol